Rexahn Pharmaceuticals Inc.
15245 Shady Grove Road, Suite 470
Rockville MD 20850
Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahnâ€™s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Companyâ€™s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.